[Effect of adjuvant infusion therapy of low molecular weight dextrans (Infukoll M 40) and deproteinized hemoderivate (Actovegin) in Fontaine stage IV chronic arterial occlusive diseases].
A selected group of 18 patients (among them 16 diabetics) with chronic disorders of arterial blood flow at Stage IV according to Fontaine received treatment by a standardised therapeutic scheme. None of the cases was suitable for reconstruction by vascular surgery. Infusion treatment, using Infukoll M 40 and Actovegin, was to be checked for its capability of providing sufficient improvement in blood flow and thus eliminating the need for imminent high-level amputation. Evaluation was undertaken on the basis of clinical and laboratory-chemical parameters. The rate of above-knee amputation was reduced by 14 per cent. Hence, the above therapeutic concept has proved to be suitable for treatment of Stage IV chronic arterial occlusion.
Stoltz
J
J
Klinik und Poliklinik für Chirurgie des Bereichs Medizin, Friedrich-Schiller-Universität Jena.
Bartel
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003911:Dextrans / Q000008:administration & dosage*; D005260:Female; D006418:Heme / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006438:Hemodilution / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D007511:Ischemia / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood
D003911:Dextrans; D006418:Heme; C015646:Actovegin; D010100:Oxygen
Einfluss einer adjuvanten Infusionstherapie von niedermolekularen Dextranen (Infukoll M 40) und deproteinisiertem Hämoderivat (Actovegin) bei chronisch arteriellen Durchblutungsstörungen im Stadium IV nach Fontaine.